Vela Diagnostics has released a new Sentosa SA NRAS PCR test, the only automated NRAS qPCR test available to detect mutations related to melanoma and thyroid cancers. The NRAS test is currently labeled for research use only.
NRAS is a member of the Ras family of oncogenes and is associated with the efficacy of drugs targeted toward malignant melanoma. The test could help identify early stages of thyroid cancers like papillary thyroid carcinoma, which appear to be on the rise, according to Vela.
“We are excited to be the first in the market to launch an NRAS test that is highly sensitive and robust to detect NRAS mutations,” said Michael Tillman, CEO of Vela. “With recent ongoing clinical trials, this will be a revolutionary test for companion diagnostics.”
The Sentosa SA NRAS PCR test joins Vela?s qPCR oncology panel, which currently includes BRAF tests and will feature an upcoming KRAS test. The company also plans to introduce next-generation sequencing tests in 2014.
The Sentosa NRAS PCR test is validated for the Sentosa qPCR automated workflow, which currently supports more than 20 tests. The workflow features automated reporting and middleware capability to provide sample traceability and result calling. For more information, visit Vela Diagnostics.
